Dailymotion Ema

3.4/ 5stars

❂↓✦⬇♢✱✻⌘✵

DOWNLOAD &STREAM

123Movies >>>

⦂∞✰❃✶♢⇪✸✹

 

 

Columnist - Equity Management Academy

Runtime=124 Minute; star=Josh O'Connor, Anya Taylor-Joy; Release date=2020; genre=Comedy; Ema Recommend Download Ema Vioz Solar Movies Ema Full"Movie. ….

Emma. cast. I don't understand a single comment. I'm gonna learn Spanish. Emma and wendy.

Watch Ema Online Freeform Watch Ema Online Vidzi

 

I saw her genius interview, mabel sings very well and just needs to learn to sing while dancing, she looked a bit out of breath, but im sure she will improve. Esta en spotify. Di Mi Nombre. Emma roberts. EU flags are up in EMA’s new building in Amsterdam Relocation Netherlands The EU flags have now been raised in the lobby of EMA’s new and final building in Amsterdam. This marks the end of the Agency’s relocation journey. UK withdrawal from the EU on 31 January 2020 Brexit Regulatory The United Kingdom formally left the European Union on 31 January 2020 and became a third country to the EU. On 1 February 2020, a transition period started which is due to end on 31 December 2020. CHMP highlights: January 2020 MEDICINES COMMITTEES EMA’s human medicines committee (CHMP) recommended fifteen medicines for approval at its 27-30 January meeting. Key principles for the use of electronic product information for EU medicines Key principles ePI A harmonised approach to develop and use electronic product information (ePI) for human medicines across the EU is outlined in the final key principles now published. Search for medicines Search for information on human, veterinary or herbal medicines. What's new Find all the latest news and updates published on this website in one place. FAQs Find answers to the most frequently asked questions we receive. Latest news List item 03/02/2020 EMA’s staff gathered today to raise the EU flags in the lobby of its new and final building in Amsterdam. “A year ago, we lowered the flags in our London offices with a heavy heart. With this flag-raising ceremony in our new Amsterdam home, we can... 31/01/2020 The United Kingdom will formally leave the European Union on 31 January 2020 and will become a third country to the EU. On 1 February 2020 a transition period will start which is due to end on 31 December 2020. During the transition period, EU... Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2020 Fifteen new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended fifteen medicines for approval at its January 2020 meeting. The Committee recommended granting a marketing authorisation for Givlaari* (givosiran), the... First oral GLP-1 treatment for type 2 diabetes EMA’s human medicines committee (CHMP) has recommended granting a marketing authorization in the European Union (EU) for Rybelsus (semaglutide) for the treatment of adults with insufficiently controlled type 2 diabetes to improve glycaemic control... First treatment for acute hepatic porphyria EMA’s human medicines committee (CHMP) has recommended granting a marketing authorisation in the European Union (EU) for Givlaari (givosiran), the first treatment for acute hepatic porphyria (AHP) in adults and adolescents aged 12 years and older... 29/01/2020 EMA, the Heads of Medicines Agencies (HMA) of EU Member States and the European Commission (EC) have published today key principles outlining a harmonised approach to develop and use electronic product information (ePI) for human medicines across... Load more news Information for Patients and carers Featured news and updates for patients and carers Healthcare professionals Featured news and updates for healthcare professionals, including doctors, nurses and pharmacists Animal health professionals Featured news and updates for animal health professionals and users of veterinary medicines such as pet owners Pharmaceutical industry Featured news and updates for pharmaceutical industry stakeholders active in the human and veterinary medicines fields Media Featured news and updates for journalists with a professional interest in the development and availability of medicines in the European Union Academia Featured news and updates for European academics and researchers in the field of medicine development Key content Product emergency hotline UK’s withdrawal from the EU PRIME: Priority medicines Pharmacovigilance (safety monitoring) Data on medicines Clinical data publication Careers Services & databases Account Management portal eSubmission EudraVigilance (human) EU Veterinary Medicinal Product Database Suspected adverse drug reactions database Clinical data SPOR data management services Service Desk IRIS platform Public register of parallel distribution notices How does EMA work? What we do Our role in authorisation of medicines Who we are Our scientific experts How we work What we publish.

Gratuluji 👍👍👍. Nicolas Jaar bajo seudónimo, una joya. This reminds me of the killjoys/danger day vibes. Emma afra. She can sing, rap and dance. Shes pretty well rounded. What is Exponential Moving Average - EMA? An exponential moving average (EMA) is a type of moving average (MA) that places a greater weight and significance on the most recent data points. The exponential moving average is also referred to as the exponentially weighted moving average. An exponentially weighted moving average reacts more significantly to recent price changes than a simple moving average (SMA), which applies an equal weight to all observations in the period. TradingView. Key Takeaways The EMA is a moving average that places a greater weight and significance on the most recent data points. Like all moving averages, this technical indicator is used to produce buy and sell signals based on crossovers and divergences from the historical average. Traders often use several different EMA days, for instance, 20-day, 30-day, 90-day, and 200-day moving averages. The Formula For EMA Is  E M A Today = ( Value Today ∗ ( Smoothing 1 + Days)) where: begin{aligned} &begin{aligned} EMA_{text{Today}}=&left(text{Value}_{text{Today}}astleft(frac{text{Smoothing}}{1+text{Days}}right)right) &+EMA_{text{Yesterday}}astleft(1-left(frac{text{Smoothing}}{1+text{Days}}right)right)end{aligned} &textbf{where:} &EMA=text{Exponential moving average} end{aligned} ​ E M A Today ​ = ​ ( Value Today ​ ∗ ( 1 + Days Smoothing ​)) ​ where: ​  The three basic steps to calculating the EMA are: Calculate the SMA. Calculate the multiplier for smoothing/weighting factor for the previous EMA. Calculate the current EMA. Calculating the EMA To calculate an EMA, you must first compute the simple moving average (SMA) over a particular time period. The calculation for the SMA is straightforward: it is simply the sum of the stock's closing prices for the number of time periods in question, divided by that same number of periods. So, for example, a 20-day SMA is just the sum of the closing prices for the past 20 trading days, divided by 20. Next, you must calculate the multiplier for smoothing (weighting) the EMA, which typically follows the formula: [2 ÷ (selected time period + 1)]. So, for a 20-day moving average, the multiplier would be [2/(20+1)]= 0. 0952. Finally, to calculate the current EMA, the following formula is used: [Closing price-EMA (previous day)] x multiplier + EMA (previous day) The EMA gives a higher weighting to recent prices, while the SMA assigns equal weighting to all values. The weighting given to the most recent price is greater for a shorter-period EMA than for a longer-period EMA. For example, an 18. 18% multiplier is applied to the most recent price data for a 10-period EMA, whereas for a 20-period EMA, only a 9. 52% multiplier weighting is used. There are also slight variations of the EMA arrived at by using the open, high, low or median price instead of using the closing price. Simple Vs. Exponential Moving Averages What Does The Exponential Moving Average Tell You? The 12- and 26-day exponential moving averages (EMAs) are often the most popularly quoted or analyzed short-term averages. The 12- and 26-day are used to create indicators like the moving average convergence divergence (MACD) and the percentage price oscillator (PPO). In general, the 50- and 200-day EMAs are used as signals of long-term trends. When a stock prices crosses its 200-day moving average, it is a technical indicator that a reversal has occurred. Traders who employ technical analysis find moving averages very useful and insightful when applied correctly but create havoc when used improperly or are misinterpreted. All the moving averages commonly used in technical analysis are, by their very nature, lagging indicators. Consequently, the conclusions drawn from applying a moving average to a particular market chart should be to confirm a market move or to indicate its strength. Very often, by the time a moving average indicator line has made a change to reflect a significant move in the market, the optimal point of market entry has already passed. An EMA does serve to alleviate this dilemma to some extent. Because the EMA calculation places more weight on the latest data, it “hugs” the price action a bit more tightly and therefore reacts more quickly. This is desirable when an EMA is used to derive a trading entry signal. Interpreting the EMA Like all moving average indicators, they are much better suited for trending markets. When the market is in a strong and sustained uptrend, the EMA indicator line will also show an uptrend and vice-versa for a down trend. A vigilant trader will not only pay attention to the direction of the EMA line but also the relation of the rate of change from one bar to the next. For example, as the price action of a strong uptrend begins to flatten and reverse, the EMA’s rate of change from one bar to the next will begin to diminish until such time that the indicator line flattens and the rate of change is zero. Because of the lagging effect by this point, or even a few bars before, the price action should have already reversed. It follows, therefore, that observing a consistent diminishing in the rate of change of the EMA could itself be used as an indicator that could further counter the dilemma caused by the lagging effect of moving averages. Common Uses of the EMA EMAs are commonly used in conjunction with other indicators to confirm significant market moves and to gauge their validity. For traders who trade intraday and fast-moving markets, the EMA is more applicable. Quite often, traders use EMAs to determine a trading bias. For example, if an EMA on a daily chart shows a strong upward trend, an intraday trader’s strategy may be to trade only from the long side on an intraday chart. The Difference Between EMA and SMA More specifically, the EMA gives a higher weighting to recent prices, while the SMA assigns equal weighting to all values. The two averages are similar because they are interpreted in the same manner and are both commonly used by technical traders to smooth out price fluctuations. Since EMAs place a higher weighting on recent data than on older data, they are more reactive to the latest  price changes  than SMAs are, which makes the results from EMAs more timely and explains why the EMA is the preferred average among many traders. Limitations Of The EMA It is unclear whether or not more emphasis should be placed on the most recent days in the time period or on more distant data. Many traders believe that new data will better reflect the current trend the security is moving with; meanwhile others feel that privileging certain dates than others will biases the trend. Therefore, the EMA is subject to recency bias. Similarly, the EMA relies wholly on historical data. Many people (including economists) believe that markets are efficient - that is, that current market prices already reflect all available information. If markets are indeed efficient, using historical data should tell us nothing about the future direction of asset prices.

1:35. spoiler alert. Imagine in this moment reiner comes out to fight eren in chapter 104. Menu Spreads served with our house bread za'atar, vegetable crudité marinated fresno & sweet roasted chilies marcona almonds, roasted grapes, burnt honey Toasted Almond & Garlic $8. 95 castelvetrano olives, fresh herbs house yogurt, lemon, california arbequina olive oil sun dried tomato, basil, lemon oil Roasted Mushroom Hummus $10. 95 truffel vinaigrette, toum, lemon zest *Consuming raw or under-cooked meats, poultry, seafood, shellfish, or eggs may increase risk of illness from food Last updated: February 4, 2020.

1:34 when you summon an army of Shibes. The outfit. The hair. The performance. EVERYTHING. European Medicines Agency Agency overview Formed 1 January 1995; 25 years ago Jurisdiction European Union Headquarters Amsterdam, Netherlands [1] Motto Science. Medicines. Health. Agency executives Guido Rasi, Executive Director Christa Wirthumer-Hoche, Chairperson Key document Regulation (EC) No. 726/2004 Website ema Map Amsterdam European Medicines Agency (European Union) European Union This article is part of a series on the politics and government of the European Union Member States (27)   Austria   Belgium   Bulgaria   Croatia   Cyprus   Czech Republic   Denmark   Estonia   Finland   France   Germany   Greece   Hungary   Ireland   Italy   Latvia   Lithuania   Luxembourg   Malta   Netherlands   Poland   Portugal   Romania   Slovakia   Slovenia   Spain   Sweden Presidency of the Council of the EU Croatia (January - June 2020) Candidate countries Albania Bosnia and Herzegovina Montenegro North Macedonia Serbia Turkey Special member state territories EU 3 Withdrawal from the European Union The Treaties Treaty of Paris (1951) Treaty of Rome (1957) Euratom Treaty (1957) Merger Treaty (1965) Single European Act (1986) Maastricht Treaty (1992) Amsterdam Treaty (1997) Treaty of Nice (2001) Treaty of Lisbon (2007) Article 7 Article 50 Opt-outs Treaties of Accession 1972, 1979, 1985, 1994, 2003, 2005, 2011 Other Treaties Schengen Agreement (1985) EEA Agreement (1992) Brexit Withdrawal Agreement (2018) Abandoned treaties and agreements European Constitution (2004) UK renegotiation of EU membership (2015-16) Executive European Council President: Michel (ALDE) Parties List of meetings European Commission Von der Leyen Commission President: Von der Leyen (EPP) Vice Presidents College of Commissioners Civil Service Secretary-General: Juhansone Legislature Legislative procedure Council of the EU ( Presidency) Configurations General Foreign Economic Eurogroup Justice and Home Voting Secretariat Secretary-General: Uwe Corsepius Directorates-general COREPER European Parliament ( Members) President: Sassoli (S&D) Largest groups EPP ( Manfred Weber) S&D ( Iratxe García) Member of the European Parliament 9th session (2019–24) Bureau Quaestor Conference National parliaments Judiciary Court of Justice of the EU Court of Justice Members Rulings General Court Euro Eurozone Members Austria Belgium Cyprus Estonia Finland France Germany Greece Ireland Italy Latvia Lithuania Luxembourg Malta Netherlands Portugal Slovakia Slovenia Spain President Mário Centeno European Central Bank President Draghi ESCB EMU Schengen Area Participating Schengen Area States Czech Republic Denmark Hungary Iceland (non-EU state) Liechtenstein (non-EU state) Norway (non-EU state) Poland Sweden Switzerland (non-EU state) Prüm Convention Schengen Information System Visa Information System Visa policy of the Schengen Area European Economic Area EEA Members Bulgaria Romania United Kingdom (non-EU state) Gibraltar EEA Joint Committee EEA National Identity cards Microstates and the European Union Court of Auditors Budget OLAF Other Bodies European Atomic Energy Community Agencies Investment Bank CoR EESC Ombudsman Former European Bodies European Communities (1958-1993) European Coal and Steel Community European Economic Community Law Acquis Primacy Subsidiarity Regulation Directive Decision Fundamental Rights Policies and Issues Customs Union Free Trade Agreements European Single Market Area of FS&J Policies Agricultural Energy Fisheries Regional Citizenship Passports of the European Union Identity Pro-Europeanism Euroscepticism Integration Supranationalism Federalism United States of Europe Enhanced co-op Elections 1979, 1984, 1989, 1994 1999, 2004, 2009, 2014 2019 (last election) Political parties Constituencies Referendums Other Other currencies in use Bulgarian lev Croatian kuna Czech koruna Danish krone Hungarian forint Polish złoty Romanian leu Swedish krona ERM II Enlargement of the Eurozone Bulgaria and the euro Croatia and the euro Czech Republic and the euro Denmark and the euro Hungary and the euro Poland and the euro Sweden and the euro Romania and the euro Non-Schengen Area States Croatia Common Travel Area ( Ireland) Multi-speed Europe Foreign Relations High Representative Josep Borrell Foreign relations of EU Member States Ext. Action Service Foreign Policy Defence Policy European Union Association Agreement Norway–European Union relations Switzerland–European Union relations United Kingdom–European Union relations United States-European Union relations European Union and the United Nations G7 G20 European Union portal Other countries Atlas v t e The European Medicines Agency ( EMA) is an agency of the European Union (EU) in charge of the evaluation and supervision of medicinal products. Prior to 2004, it was known as the European Agency for the Evaluation of Medicinal Products or European Medicines Evaluation Agency ( EMEA). [2] [3] The EMA was set up in 1995, with funding from the European Union and the pharmaceutical industry, as well as indirect subsidy from member states, its stated intention to harmonise (but not replace) the work of existing national medicine regulatory bodies. The hope was that this plan would not only reduce the €350 million annual cost drug companies incurred by having to win separate approvals from each member state but also that it would eliminate the protectionist tendencies of sovereign states unwilling to approve new drugs that might compete with those already produced by domestic drug companies. The EU is currently the source of about one-third of the new drugs brought onto the world market each year. [ not verified in body] The EMA was founded after more than seven years of negotiations among EU governments and replaced the Committee for Proprietary Medicinal Products and the Committee for Veterinary Medicinal Products, though both of these were reborn as the core scientific advisory committees. The agency was located in London prior to the United Kingdom's vote for withdrawal from the European Union, relocating to Amsterdam in March 2019. [4] [5] Operations [ edit] The EMA operates as a decentralised scientific agency (as opposed to a regulatory authority) of the European Union and its main responsibility is the protection and promotion of public and animal health, through the evaluation and supervision of medicines for human and veterinary use. More specifically, it coordinates the evaluation and monitoring of centrally authorised products and national referrals, develops technical guidance and provides scientific advice to sponsors. Its scope of operations is medicinal products for human and veterinary use including biologics and advanced therapies, and herbal medicinal products. The agency is composed of the Secretariat (ca. 600 staff), a management board, seven scientific committees (human, veterinary and herbal medicinal products, orphan drugs, paediatrics, advanced therapies and pharmacovigilance risk assessment) and a number of scientific working parties. The Secretariat is organised into five units: Directorate, Human Medicines Development and Evaluation, Patient Health Protection, Veterinary Medicines and Product Data Management, Information and Communications Technology and Administration. The Management Board provides administrative oversight to the Agency: including approval of budgets and plans, and selection of Executive Director. The Board includes one representative of each of the 28 Member States, two representatives of the European Commission, two representatives of the European Parliament, two representatives of patients' organisations, one representative of doctors' organisations and one representative of veterinarians' organisations. The Agency decentralises its scientific assessment of medicines by working through a network of about 4500 experts throughout the EU. The EMA draws on resources of over 40 National Competent Authorities (NCAs) of EU Member states. [ edit] The centralised procedure allows companies to submit a single application to the agency to obtain from the European Commission a centralised (or 'Community') marketing authorisation (MA) valid in all EU and European Economic Area (EEA)- European Free Trade Association (EFTA) states ( Iceland, Liechtenstein and Norway). The centralised procedure is compulsory for all medicines derived from biotechnology and other high-tech processes, as well as for human medicines for the treatment of HIV/AIDS, cancer, diabetes, neurodegenerative diseases, auto-immune and other immune dysfunctions, and viral diseases, and for veterinary medicines for use for growth or yield enhancers. The centralised procedure is also open to products that bring a significant therapeutic, scientific or technical innovation, or is in any other respect in the interest of patient or animal health. As a result, the majority of genuinely novel medicines are authorised through the EMA. For products eligible for or requiring centralised approval, a company submits an application for a marketing authorisation to the EMA. [ citation needed] Committees [ edit] Committee for Medicinal Products for Human Use [ edit] A single evaluation is carried out through the Committee for Medicinal Products for Human Use (CHMP). If the Committee concludes that the quality, safety and efficacy of the medicinal product is sufficiently proven, it adopts a positive opinion. This is sent to the European Commission to be transformed into a marketing authorisation valid for the whole of the EU. A special type of approval is the paediatric-use marketing authorisation (PUMA), which can be granted for medical products intended exclusively for paediatric use. [6] The CHMP is obliged by the regulation to reach decisions within 210 days, though the clock is stopped if it is necessary to ask the applicant for clarification or further supporting data. [ citation needed] Committee for Medicinal Products for Veterinary Use [ edit] The Committee for Medicinal Products for Veterinary Use (CVMP) operates in analogy to the CHMP as described above. [ citation needed] Committee on Orphan Medicinal Products [ edit] The Committee on Orphan Medicinal Products (COMP) administers the granting of orphan drug status since 2000. Companies intending to develop medicinal products for the diagnosis, prevention or treatment of life-threatening or very serious conditions that affect not more than five in 10, 000 persons in the European Union can apply for 'orphan medicinal product designation'. The COMP evaluates the application and makes a recommendation for the designation which is then granted by the European Commission. [ citation needed] Committee on Herbal Medicinal Products [ edit] The Committee on Herbal Medicinal Products (HMPC) assists the harmonisation of procedures and provisions concerning herbal medicinal products laid down in EU Member States, and further integrating herbal medicinal products in the European regulatory framework since 2004. Paediatric Committee [ edit] The Paediatric Committee (PDCO) deals with the implementation of the paediatric legislation in Europe Regulation(EC) No 1901/2006 since 2007. Under this legislation, all applications for marketing authorisation of new medicinal products, or variations to existing authorisations, have to either include data from paediatric studies previously agreed with the PDCO, or obtain a PDCO waiver or a deferral of these studies. Committee for Advanced Therapies [ edit] The Committee for Advanced Therapies (CAT) was established in accordance with Regulation (EC) No 1394/2007 on advanced-therapy medicinal products (ATMPs) such as gene therapy, somatic cell therapy and tissue engineered products. It assesses the quality, safety and efficacy of ATMPs, and follows scientific developments in the field. [7] Pharmacovigilance Risk Assessment Committee [ edit] A seventh committee, the Pharmacovigilance Risk Assessment Committee (PRAC) has come into function in 2012 with the implementation of the new EU pharmacovigilance legislation (Directive 2010/84/EU). [8] Other activities [ edit] The Agency carries out a number of activities, including: Pharmacovigilance: The Agency constantly monitors the safety of medicines through a pharmacovigilance network and EudraVigilance, so that it can take appropriate actions if adverse drug reaction reports suggest that the benefit-risk balance of a medicine has changed since it was authorised. Referrals: The Agency coordinates arbitration procedures relating to medicinal products that are approved or under consideration by Member States in non-centralized authorisation procedures. Scientific Advice: Companies wishing to receive scientific advice from the CHMP or CVMP on the appropriate tests and studies to carry out in the development of a medicinal products can request it prior to or during the development program. Telematics projects: The Agency is responsible for implementing a central set of pan-European systems and databases such as EudraVigilance, EudraCT and EudraPharm. Relocation [ edit] Following the 2016 decision of the United Kingdom to leave the European Union (" Brexit "), the EMA chose to search for another base of operations. According to EU Law the European Commission had to decide on the fate of the EMA's location. The EU ministers met to vote on their preferred successor. [9] The EU's Health Commissioner Vytenis Andriukaitis said that the preferred choice would be a location where an "easy set up and guarantee of smooth operations" would be available. Member states who had expressed their bid for the new EMA location were Austria, [10] Belgium, Bulgaria, [11] Croatia, [10] Cyprus, [10] Czech Republic, [10] Denmark, [10] Finland, [12] France, [10] Germany, [10] Greece, [10] Hungary, [10] Ireland, [10] Italy, [10] Malta, [10] the Netherlands, [13] Poland, [11] Portugal, [14] Romania, [15] [16] Slovakia, [10] Slovenia, [10] Spain, [10] and Sweden. [17] [18] [19] It had also been speculated that the Strasbourg -based seat for the European Parliament could be moved to Brussels, in exchange for the city to host the EMA. [20] Others speculated on the merits of Amsterdam, well before the final decision was made. [21] [22] The decision on the relocation was made on 20 November 2017, during the EU General Affairs Council meeting, [22] after three voting rounds and finally drawing of lots. After the first round of voting, Milan (25 votes), Amsterdam (20 votes) and Copenhagen (20 votes) were the only contenders left. [23] After the second voting round, two cities were left: Milan (twelve votes) and Amsterdam (nine votes). These two cities tied in the subsequent vote (thirteen votes each), after which a drawing of lots identified Amsterdam as the host city of EMA. It is unclear what future arrangements the United Kingdom proposes to make for its own medicinal evaluation after leaving the EU. Paul Workman, the president of the London-based Institute of Cancer Research, has suggested that pharmaceutical companies would naturally seek regulatory approval for new drugs in the biggest markets first, leaving the UK facing delays in approval if they set up independent arrangements. [24] Criticism of the EMA process [ edit] The review process of the European Medicines Agency regarding medical issues has been criticized for its lack of transparency and issues of conflict of interest. [25] In a rebuttal of an EMS review that included her work, Louise Brinth, a Danish physician, noted that "experts" reviewing data remain unnamed and seem to be bound to secrecy. Minutes are not released and diverging opinions are not reported suggesting that all the "experts" are of the same opinion. In her view the process is unscientific and undemocratic. [26] Comparison with other regulatory agencies [ edit] The EMA is roughly parallel to the drug part of the U. S. Food and Drug Administration (FDA), [27] but without centralisation. [28] The timetable for product approval via the EMA's centralised procedure of 210 days compares well with the average of 500 days taken by the FDA to evaluate a product. [29] See also [ edit] References [ edit] ^ "Relocation to Amsterdam". European Medicines Agency. 17 September 2018. Retrieved 16 September 2019. ^ Set up by EC Regulation No. 2309/93 as the European Agency for the Evaluation of Medicinal Products, and renamed by EC Regulation No. 726/2004 to the European Medicines Agency, it had the acronym EMEA until December 2009. The European Medicines Agency does not call itself EMA either – it has no official acronym but may reconsider if EMA becomes commonly accepted (see communication on new visual identity Archived 1 June 2010 at the Wayback Machine and logo Archived 25 December 2009 at the Wayback Machine). ^ "EMEA becomes EMA". PMLive. 14 December 2009. ^ Hrabovszki, Georgina (11 March 2019). "EMA now operating from Amsterdam". Retrieved 12 March 2019. ^ "United Kingdom's withdrawal from the European Union ('Brexit')". Retrieved 16 September 2019. ^ "Questions and answers on the paediatric use marketing authorisation (PUMA)" (PDF). 13 September 2011. Archived from the original (PDF) on 15 April 2016. ^ European Medicines Agency (3 December 2019). "Committee for Advanced Therapies (CAT)". Retrieved 3 December 2019. ^ European Medicines Agency (3 December 2019). "Pharmacovigilance Risk Assessment Committee (PRAC)". Retrieved 3 December 2019. ^ "European Council - Offers to host the European Medicines Agency (EMA)". Retrieved 14 September 2017. ^ a b c d e f g h i j k l m n o "Reuters - Twenty-one countries vie to host EU drug agency after Brexit". Retrieved 10 August 2017. ^ a b "European Council - Offers to host the European Medicines Agency (EMA)". Retrieved 10 August 2017. ^ "Finland is an excellent place for European Medicines Agency". Sosiaali- ja terveysministeriö. Retrieved 18 April 2017. ^ "Homepage - The Dutch Bid for EMA". The Dutch Bid for EMA. Archived from the original on 14 July 2017. Retrieved 13 July 2017. ^ "Countries line up to host European Medicines Agency after it leaves UK". 15 February 2017. Retrieved 8 May 2017. ^ "Romania looks to poach EU medicines agency from UK". 23 March 2017. Retrieved 8 May 2017. ^ "A Brexit pill for Romania". 13 April 2017. Retrieved 8 May 2017. ^ Patrick Wintour. "Countries line up to host European Medicines Agency after it leaves UK | World news". The Guardian. Retrieved 1 April 2017. ^ Julia Bradshaw (8 December 2016). "Sweden launches campaign to host EU drugs agency instead of UK after Brexit".. Retrieved 1 April 2017. ^ Andreja Zapcic (29 March 2017). "Kujundžić: Hrvatska je spremna preuzeti Europsku agenciju za lijekove" (in Croatian).. Retrieved 1 April 2017. ^ "Strasbourg could trade Parliament seat for medicines agency". 10 May 2017. ^ "PharmaTimes, 27th September 2017. EMA staff favour move to Amsterdam". Retrieved 19 October 2017. ^ a b "Nature News, October 2017. European drug regulation at risk of stalling as agency prepares to leave London". Retrieved 13 October 2017. ^ "Ema, Milano passa al secondo turno di votazioni con Amsterdam e Copenhagen" (in Italian). Retrieved 20 October 2017. ^ "Brexit: People will die because of plans to set up UK-only drug regulator, cancer specialist warns". Independent. 10 February 2017. Retrieved 11 February 2017. ^ "Our news".. ^ Louise Brinth: Responsum to Assessment Report on HPV-vaccines released by EMA November 26th 2015., online (PDF; 1, 3 MB) ^ Gu, A; Patel, D; Nayak, R (2016). "Chapter 10: Drug shortages". In Fulda, TR; Lyles, A; Wertheimer (eds. ). Pharmaceutical Public Policy. CRC Press. pp. 151–160. ISBN   9781498748513. ^ Boslaugh, SE (2015). "European Medicines Agency". The SAGE Encyclopedia of Pharmacology and Society. SAGE Publications. ISBN   9781506346182. ^ Sherwood, Ted (16 April 2008). "Generic Drugs: Overview of ANDA Review Process" (PDF). Food and Drug Administration. Archived from the original (PDF) on 19 January 2017. Retrieved 30 January 2010. Further reading [ edit] McCormick, John (2004). The European Union: Politics and Policies. Boulder, Colo: Westview Press. ISBN   0-8133-4202-3. External links [ edit] Official website EMA Annual Report 2018 Heads of Medicines Agencies The Rules Governing Medicinal Products in the European Union (EudraLex) Health-EU Portal official public health portal of the European Union.

Emma. trailer. Emma watson. Emma. disney. princess. Look up EMA, Ema, ema, or -ema in Wiktionary, the free dictionary. Ema or EMA may refer to: People [ edit] Ema Burgić Bucko (born 1992), Bosnian tennis player Ema Derossi-Bjelajac (born 1926), Croatian politician Ema Fujisawa (born 1982), Japanese model and actress Ema Klinec (born 1998), Slovenian ski jumper Ema Kogure (born 1976), Japanese voice actress Ema Kuribayashi (born 1983), Japanese cricketer Ema Pukšec (1834–1889), Polish soprano Ema Ramusović (born 1996), Montenegrin handball player Ema Saikō (1787–1861), Japanese painter, poet, and calligrapher Ema Tōyama (born 1981), Japanese manga artist Ema Twumasi (born 1997), Ghanaian footballer Ema Wolf (born 1948), Argentine writer and journalist Erika M. Anderson (born 1982), stage name EMA, American singer/songwriter Arts and entertainment [ edit] Egmont Manga & Anime, a German manga publishing company Entertainment Merchants Association, an international trade association Environmental Media Association, an American environmental organisation Environmental Media Awards European Mahjong Association Mother (2016 Estonian film) (Estonian: Ema) Ema (film), an upcoming Chilean drama film Music [ edit] EMA (Slovenia), Slovenian Eurovision Song Contest selection Entertainment Monitoring Africa, a South African record chart Erika M. Anderson (born 1982), American singer whose stage name is EMA Eska Music Awards, a Polish awards ceremony MTV Europe Music Award Education [ edit] Eastern Military Academy, a defunct school in Connecticut Education Maintenance Allowance, in the United Kingdom Escuela Mexicana Americana, a school in Mexico City Government [ edit] Emergency Management Australia, an agency of the Australian Government Energy Market Authority, a regulatory body in Singapore Ethiopian Mapping Authority Emergency Mobile Alert, New Zealand's nationwide mobile public warning system Medicine [ edit] Anti-Endomysial Antibodies test Emergency Medicine Australasia, a scholarly journal Epithelial membrane antigen European Medicines Agency, a European Union agency for the evaluation of medicinal products European Medical Association Science and technology [ edit] Effective medium approximations Electromagnetic articulography Exponential moving average Other uses [ edit] Ema (Shinto), wooden plaques used by Shintō and Buddhist worshippers East Midlands Airport, in England Electronic Money Association, a European trade body Emmet Monument Association, a mid-nineteenth century American Irish nationalist group Engineers' and Managers' Association, a former British trade union Euro-Mediterranean Association for Cooperation and Development, a German international co-operation organization Greater rhea ( Rhea americana), a flightless bird of South America Kemak people, a Timorese ethnic group See also [ edit] Emma (disambiguation) Europe, the Middle East and Africa (EMEA).

Emma. and. jennie. Emma. chamberlain merch. Esta mujer es una bomba. No escucho su música ni puede que me gusten muchas cosas de ella. Pero es una animal! Una bestia de artista y del escenario.